doxecitine and doxribtimine
Sponsors
UCB Biosciences Inc., Hospital Universitario 12 De Octubre, UCB BIOSCIENCES, Inc., Cristina Domínguez González
Conditions
Mitochondrial MyopathiesOrganic compoundThymidine Kinase 2 (TK2 ) DeficiencyThymidine Kinase 2 DeficiencyThymidine kinase 2 deficiencyThymine Kinase 2 Deficiency
Phase 2
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
CompletedNCT03845712
Start: 2019-07-05End: 2026-08-26Updated: 2026-09-08
A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2)
Active, not recruitingCTIS2023-510427-29-00
Start: 2019-09-04Target: 23Updated: 2025-10-10
An Off-Label Single Arm Clinical Study to Evaluate the Efficacy and Safety of doxecitine and doxribtimine in Adult Subjects with Thymidine Kinase 2 (TK2) Deficiency
Not yet recruitingCTIS2024-510763-35-00
Target: 15Updated: 2025-06-04
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
RecruitingNCT06754098
Start: 2025-01-01End: 2027-12-31Target: 15Updated: 2026-09-17